ATE370139T1 - Pyrazolopyridin derivate als tgf beta hemmstoffe zur behandlung von krebs - Google Patents

Pyrazolopyridin derivate als tgf beta hemmstoffe zur behandlung von krebs

Info

Publication number: ATE370139T1
Authority: AT; Austria
Prior art keywords: cancer; treatment; tgf beta; beta inhibitors; pyrazolopyridine derivatives
Prior art date: 2002-09-17

Application number

AT03749105T

Other languages

English (en)

Inventor

Douglas Beight

Rosanne Bonjouklian

Junkai Liao

William Mcmillen

Brandon Parkhurst

Jason Sawyer

Jonathan Yingling

Jeremy York

Original Assignee

Lilly Co Eli

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2002-09-17

Filing date

2003-09-16

Publication date

2007-09-15

2003-09-16 Application filed by Lilly Co Eli filed Critical Lilly Co Eli

2007-09-15 Application granted granted Critical

2007-09-15 Publication of ATE370139T1 publication Critical patent/ATE370139T1/de

Links

206010028980 Neoplasm Diseases 0.000 title abstract 2
201000011510 cancer Diseases 0.000 title abstract 2
239000003112 inhibitor Substances 0.000 title abstract 2
150000005229 pyrazolopyridines Chemical class 0.000 title 1
ZRKFYGHZFMAOKI-QMGMOQQFSA-N tgfbeta Chemical group C([C@H](NC(=O)[C@H](C(C)C)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CC(C)C)NC(=O)CNC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)CCSC)C(C)C)[C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(O)=O)C1=CC=C(O)C=C1 ZRKFYGHZFMAOKI-QMGMOQQFSA-N 0.000 abstract 2
102000004887 Transforming Growth Factor beta Human genes 0.000 abstract 1
108090001012 Transforming Growth Factor beta Proteins 0.000 abstract 1
201000010099 disease Diseases 0.000 abstract 1
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
239000008177 pharmaceutical agent Substances 0.000 abstract 1
-1 pyrazolopyridine derivative compounds Chemical class 0.000 abstract 1
230000019491 signal transduction Effects 0.000 abstract 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents

Landscapes

Organic Chemistry (AREA)
Chemical & Material Sciences (AREA)
Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
General Health & Medical Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Chemical Kinetics & Catalysis (AREA)
Animal Behavior & Ethology (AREA)
Medicinal Chemistry (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Dermatology (AREA)
Nitrogen Condensed Heterocyclic Rings (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

AT03749105T 2002-09-17 2003-09-16 Pyrazolopyridin derivate als tgf beta hemmstoffe zur behandlung von krebs ATE370139T1 (de)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
US41156002P	2002-09-17	2002-09-17

Publications (1)

Publication Number	Publication Date
ATE370139T1 true ATE370139T1 (de)	2007-09-15

Family

ID=32030690

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
AT03749105T ATE370139T1 (de)	2002-09-17	2003-09-16	Pyrazolopyridin derivate als tgf beta hemmstoffe zur behandlung von krebs

Country Status (7)

Country	Link
US (1)	US7365066B2 (de)
EP (1)	EP1543001B1 (de)
AT (1)	ATE370139T1 (de)
AU (1)	AU2003268156A1 (de)
DE (1)	DE60315677T2 (de)
ES (1)	ES2291664T3 (de)
WO (1)	WO2004026871A1 (de)

Families Citing this family (42)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
UA80295C2 (en) *	2002-09-06	2007-09-10	Biogen Inc	Pyrazolopyridines and using the same
TW200639163A (en) *	2005-02-04	2006-11-16	Genentech Inc	RAF inhibitor compounds and methods
EP2918288B1 (de)	2006-10-03	2017-08-16	Genzyme Corporation	Verwendung von TGF-beta-Antagonisten zur Behandlung von Kleinkindern mit dem Risiko der Entwicklung von bronchopulmonaler Dysplasie
EP2320737B1 (de)	2008-08-05	2013-07-17	Merck Sharp & Dohme Corp.	Pyrazolo-[1,5-a]-pyridine als mark-hemmer
FR2950345B1 (fr)	2009-09-18	2011-09-23	Sanofi Aventis	Derives acetyleniques de 5-phenyl-pyrazolopyridine, leur preparation et leur application en therapeutique
ES2574253T3 (es)	2009-12-18	2016-06-16	Mitsubishi Tanabe Pharma Corporation	Nuevo agente antiplaquetario
EP2402337A1 (de) *	2010-06-29	2012-01-04	Basf Se	Pyrazolopyridin-Verbindungen
EP2402335A1 (de) *	2010-06-29	2012-01-04	Basf Se	Pyrazolopyridin-Verbindungen
US8871744B2 (en)	2010-07-21	2014-10-28	B & G Partyers, LLC	Compounds and methods for selectively targeting tumor-associated mucins
US20140308275A1 (en)	2011-07-27	2014-10-16	Inserm (Institut National De La Sante Et De La Recherche Medicale	Methods for diagnosing and treating myhre syndrome
BR112014009789A2 (pt)	2011-10-26	2017-04-25	Seattle Children's Res Inst	cisteamina no tratamento da doença fibrótica
CN116003600A (zh)	2012-10-05	2023-04-25	卡德门企业有限公司	人抗vegfr-2/kdr抗体
SI2925757T1 (en)	2012-11-19	2018-01-31	Novartis Ag	Compounds and compositions for the treatment of parasitic diseases
US8871754B2 (en)	2012-11-19	2014-10-28	Irm Llc	Compounds and compositions for the treatment of parasitic diseases
DK2970890T3 (da)	2013-03-14	2020-05-04	Brigham & Womens Hospital Inc	Sammensætninger og fremgangsmåder til opformering og dyrkning af epitelstamceller
GB201321733D0 (en) *	2013-12-09	2014-01-22	Ucb Pharma Sa	Therapeutic agents
EP3527569B1 (de)	2014-02-03	2021-08-25	Vitae Pharmaceuticals, LLC	Dihydropyrrolopyridininhibitoren von ror-gamma zur behandlung von augentrockenheit
WO2016037016A1 (en)	2014-09-03	2016-03-10	The Brigham And Women's Hospital, Inc.	Compositions, systems, and methods for generating inner ear hair cells for treatment of hearing loss
US9663515B2 (en)	2014-11-05	2017-05-30	Vitae Pharmaceuticals, Inc.	Dihydropyrrolopyridine inhibitors of ROR-gamma
WO2016160881A1 (en)	2015-04-01	2016-10-06	Rigel Pharmaceuticals, Inc.	TGF-β INHIBITORS
ES2856931T3 (es)	2015-08-05	2021-09-28	Vitae Pharmaceuticals Llc	Moduladores de ROR-gamma
EP3868750A1 (de) *	2015-11-20	2021-08-25	Vitae Pharmaceuticals, LLC	Modulatoren von ror-gamma
JP2019506153A (ja)	2016-01-08	2019-03-07	マサチューセッツインスティテュートオブテクノロジー	分化した腸内分泌細胞およびインスリン産生細胞の作製
TW202220968A (zh)	2016-01-29	2022-06-01	美商維它藥物有限責任公司	ＲＯＲ－γ調節劑
US11260130B2 (en)	2016-03-02	2022-03-01	Frequency Therapeutics, Inc.	Solubilized compositions for controlled proliferation of stem cells / generating inner ear hair cells using a GSK3 inhibitor: IV
US10201540B2 (en)	2016-03-02	2019-02-12	Frequency Therapeutics, Inc.	Solubilized compositions for controlled proliferation of stem cells / generating inner ear hair cells using GSK3 inhibitors: I
US10213511B2 (en)	2016-03-02	2019-02-26	Frequency Therapeutics, Inc.	Thermoreversible compositions for administration of therapeutic agents
MX390321B (es)	2016-12-30	2025-03-20	Frequency Therapeutics Inc	Compuestos de 1h-pirrol-2,5-diona y metodos de uso de los mismos para inducir la auto-renovacion de celulas madre/progenitoras de soporte.
MA49685A (fr)	2017-07-24	2021-04-14	Vitae Pharmaceuticals Llc	INHIBITEURS DE ROR gamma
WO2019018975A1 (en)	2017-07-24	2019-01-31	Vitae Pharmaceuticals, Inc.	INHIBITORS OF ROR GAMMA
US10342786B2 (en)	2017-10-05	2019-07-09	Fulcrum Therapeutics, Inc.	P38 kinase inhibitors reduce DUX4 and downstream gene expression for the treatment of FSHD
WO2019071144A1 (en)	2017-10-05	2019-04-11	Fulcrum Therapeutics, Inc.	USE OF P38 INHIBITORS TO REDUCE DUX4 EXPRESSION
ES3018269T3 (en)	2017-12-13	2025-05-14	Glaxosmithkline Ip Dev Ltd	Carboxyesterase biocatalysts
AU2019240065A1 (en)	2018-03-20	2020-09-24	Icahn School Of Medicine At Mount Sinai	Kinase inhibitor compounds and compositions and methods of use
WO2020019108A1 (en)	2018-07-23	2020-01-30	Guangzhou Othrotx Co., Ltd.	Bisphosphonate drug conjugates
WO2020037326A1 (en)	2018-08-17	2020-02-20	Frequency Therapeutics, Inc.	Compositions and methods for generating hair cells by downregulating foxo
JP2021533788A (ja)	2018-08-17	2021-12-09	フリークエンシーセラピューティクスインコーポレイテッド	Ｊａｇ−１を上方制御することにより有毛細胞を生成するための組成物及び方法
CA3124700A1 (en)	2018-12-31	2020-07-09	Icahn School Of Medicine At Mount Sinai	Kinase inhibitor compounds and compositions and methods of use
US20220177978A1 (en)	2019-04-02	2022-06-09	INSERM (Institut National de la Santé et de la Recherche Médicale)	Methods of predicting and preventing cancer in patients having premalignant lesions
EP4087657A1 (de)	2020-01-08	2022-11-16	Synthis Therapeutics, Inc.	Alk5-inhibitoren, konjugate und verwendungen davon
CN113862710B (zh) *	2021-09-17	2023-11-03	阜阳师范大学	一种二氢二吡唑[3,4-b:4′,3′-e]吡啶类化合物的电化学合成方法
EP4727586A1 (de)	2023-06-13	2026-04-22	Synthis Therapeutics, Inc.	Anti-cd5-antikörper und ihre verwendungen

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
JP2001139575A (ja) *	1999-11-15	2001-05-22	Fujisawa Pharmaceut Co Ltd	新規ピラゾロピリジン誘導体
GB0102672D0 (en) *	2001-02-02	2001-03-21	Glaxo Group Ltd	Compounds
JP2004521901A (ja) *	2001-02-02	2004-07-22	グラクソ　グループ　リミテッド	Ｔｇｆ阻害剤としてのピラゾール
US20040087623A1 (en)	2001-02-02	2004-05-06	Gellibert Francoise Jeanne	Pyrazole derivatives against tgf overexpression
HRP20030961B1 (en) *	2001-05-24	2012-01-31	Eli Lilly And Company	Novel pyrrole derivatives as pharmaceutical agents

2003
- 2003-09-16 EP EP03749105A patent/EP1543001B1/de not_active Expired - Lifetime
- 2003-09-16 ES ES03749105T patent/ES2291664T3/es not_active Expired - Lifetime
- 2003-09-16 DE DE60315677T patent/DE60315677T2/de not_active Expired - Fee Related
- 2003-09-16 AU AU2003268156A patent/AU2003268156A1/en not_active Abandoned
- 2003-09-16 US US10/524,577 patent/US7365066B2/en not_active Expired - Fee Related
- 2003-09-16 WO PCT/US2003/026297 patent/WO2004026871A1/en not_active Ceased
- 2003-09-16 AT AT03749105T patent/ATE370139T1/de not_active IP Right Cessation

Also Published As

Publication number	Publication date
US7365066B2 (en)	2008-04-29
EP1543001B1 (de)	2007-08-15
ES2291664T3 (es)	2008-03-01
DE60315677D1 (de)	2007-09-27
WO2004026871A1 (en)	2004-04-01
US20050222197A1 (en)	2005-10-06
EP1543001A1 (de)	2005-06-22
AU2003268156A1 (en)	2004-04-08
DE60315677T2 (de)	2008-06-05

Similar Documents

Publication	Publication Date	Title
DE60315677D1 (de)	2007-09-27	Pyrazolopyridin derivate als tgf beta hemmstoffe zur behandlung von krebs
CY1110965T1 (el)	2015-06-11	Επιπροσθετες ετεροπολυκυκλικες ενωσεις και η χρηση τους ως ανταγωνιστες μεταβολοτροπικου υποδοχεα γλουταμικου
HUS1600021I1 (hu)	2016-06-28	MEK inhibitorok és módszerek azok felhasználására
SE0301700D0 (sv)	2003-06-10	Novel compounds
EA200900802A1 (ru)	2010-04-30	Способы и композиции для лечения амилоидных заболеваний
EA200600078A1 (ru)	2006-08-25	Способы и композиции для лечения амилоидных заболеваний
EA200800555A1 (ru)	2008-08-29	Производные ксантина в качестве селективных агонистов hm74a
DE60303238D1 (de)	2006-04-06	Pyrimidin-Essigsäure Derivate geeignet zur Behandlung von CRTH2-bedingten Krankheiten
DE602004011199D1 (de)	2008-02-21	5-phenylthiazolderivate und deren verwendung als p13-kinase-inhibitoren
EA200700188A1 (ru)	2007-06-29	Производные замещенного 2-алкилхиназолинона как ингибиторы parp
ATE438401T1 (de)	2009-08-15	1-aryl-4-substituierte piperazin-derivate zur verwendung als ccr1-antagonisten zur behandlung von entzündungen und immunerkrankungen
EA200501236A1 (ru)	2006-04-28	Аминогетероарильные соединения в качестве ингибиторов протеинкиназ
ATE442142T1 (de)	2009-09-15	Fredericamycin-derivate als arzneimittel zur tumorbehandlung
EA200801291A1 (ru)	2008-12-30	Карбониламинопирролопиразолы в качестве эффективных ингибиторов киназ
NO20056192L (no)	2005-12-27	Kapaseinhibitorer og anvendelse derav
CY1108932T1 (el)	2014-07-02	Ενωσεις 4-(ετεροκυκλυλ)-βενζολοσουλφοξιμινης για την θεραπευτικη αγωγη φλεγμονωδων ασθενειων
ECSP034859A (es)	2004-01-28	Nuevos derivados de pirrol como agentes farmacéuticos
EA200701930A1 (ru)	2008-02-28	Производные пиримидина для лечения гиперпролиферативных нарушений
BR0313385A (pt)	2005-06-14	Derivados de pirimidina-2,4-diona como inibidores de metaloproteinase da matriz
MA27880A1 (fr)	2006-05-02	Derives de tetrahydrocarbazole et leur utilisation pharmaceutique
DE602005012481D1 (de)	2009-03-12	2,7-substituierte 5-amino-4-hydroxy-8-(1h-indol-5-yl)-octanamid derivate als renin inhibitoren zur behandlung von bluthochdruck
EP1817312A4 (de)	2009-11-04	Makrozyklische aminiopyridyl-beta-sekretase-hemmer zur behandlung von morbus alzheimer
DK1730144T3 (da)	2009-10-12	Substituerede 1,4,8-triazaspiro[4.5]decan-2-on-forbindelser
SE0300457D0 (sv)	2003-02-19	Novel compounds
DE60131968D1 (de)	2008-01-31	PYRANOÄ2,3-cÜIMIDAZOÄ1,2-aÜPYRIDIN-DERIVATE ZUR BEHANDLUNG VON GASTROINTESTINALEN ERKRANKUNGEN

Legal Events

Date	Code	Title	Description
2008-02-15	RER	Ceased as to paragraph 5 lit. 3 law introducing patent treaties